COMUNICATO STAMPA SPONSORIZZATO – /C O R R E C T I O N — EirGenix, Inc./
12 Novembre 2025 | immediapress
(Immediapress) – In the news release, EirGenix Signed The Commercial Licensinse Agreement for It’s Second HER2 Biosimilar Asset EG1206A, issued 12-Nov-2025 by EirGenix, Inc. over PR Newswire, we are advised by the company that there are two typos in the headline. The complete, corrected…